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Human stem cell models for predictive cardiac safety
pharmacology‘Safety pharmacology’ is a relatively young and rapidly
developing discipline that aims to predict potential negative
effects before a new drug is first administered to patients. It
is unique in the sense that it is not only supposed to identify
the risk of rare undesirable pharmacodynamic effects on
specific cells and tissues but also the systemic effect on the
whole individual. The core focus is on the most sensitive
target organs: the liver, the central nervous system, the
respiratory system and the cardiovascular system. The
cardiovascular system is of particular interest since effects
on the heart may not only be chronic as for other organs but
may also be immediately life threatening: ‘sudden cardiac
death’ can be the tragic outcome. It is becoming increasingly
clear that drugs can pass all of the present regulatory
requirements and be authorized for prescription to patients
or even sold ‘over the counter’ for many years before rare
and lethal adverse effects become apparent. One of the
best-known examples is the drug terfenadine, used to treat
allergic rhinitis (hay fever). After being on the market for
almost 15 years, the drug was withdrawn as it became
evident that it could prolong the cardiac ‘QT interval’, the
time between two electrical peaks on an electrocardiogram
(ECG), and as a result induce serious ventricular tachyar-
rhythmias (rapid heart beat), including the potentially lethal
Torsades de Pointes (TdP).
Identification of QT interval prolongation on an ECG has
become a biomarker for TdP. It has led to the withdrawal of
several other drugs from the market in the United States,
including cisapride, thioridazine, and grepafloxacin. Many
others have been required by the Food and Drug Adminis-
tration (FDA) to carry additional safety labeling warning of
the potential risk. QT prolongation is often caused by drug
interference with the human Ether-a-go-go Related Gene
(hERG). The hERG gene encodes the Kv11.1 potassium
channel and is essential for cardiac action potential
repolarization; if blocked it will prolong the QT interval
and there will be an increased risk of ventricular arrhyth-
mias. Assessing drug-induced prolongation of the QT interval
has been the major preoccupation of cardiac safety
pharmacology, under the assumption that a prolonged QT
indicates an increased probability of TdP.1873-5061/$ – see front matter © 2010 Published by Elsevier B.V.
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however, is how best to conduct reliable high throughput
screening to predict the risk of ventricular arrhythmias at an
early stage in drug development. It is presently common
practice to screen for hERG/IKr effects using either planar
patch clamp technology or ligand binding assays. However,
these methods, although high throughput, are known to
generate false positives, false negatives and relatively
variable values for IC50 (the dose of a drug causing 50% of
the final effect) when compared to conventional (low
throughput) patch clamp electrophysiology. Pharmaceutical
companies continue to use them nevertheless but err on the
side of caution because of the wisdom of hindsight and are
now likely to avoid further development of any compounds
that show IKr blocking in these assays in early stage tests. This
may result in unnecessary rejection of potentially valuable
clinical compounds. Several drugs used in the clinic, like
verapamil for example, inhibit IKr without actually prolong-
ing the QT interval or inducing TdP, while others prolong the
action potential without inducing TdP (Shah and Honde-
ghem, 2005). hERG block at a concentration close to the
therapeutic range for a drug should be considered a serious
warning signal and warrants further study.
Several tests are based on isolated cardiac tissues. These
include Purkinje fibers, papillary muscles and ventricular
trabeculae from animals. None is yet versatile and predictive
enough to convince regulators that a drug that does not
adversely affect these tissues be regarded as safe. The
regulatory authorities usually require more complex in vivo
telemetry studies in larger animals like dogs and pigs (ICH
topic S7B). Nevertheless, it is still not possible to quantify
risk/benefit assessment for TdP liability accurately on the
basis of the current preclinical assays (Pugsley et al., 2008).
This is where cardiomyocytes derived from human pluripo-
tent stem cells may be useful. These cells have a significant
potential to be developed into a model with a relatively high
predictive value for cardiac safety pharmacology. These are
human cells and, as far as we can tell, they can share many
features of human adult ventricular cardiomyocytes and can
in principle be scaled up to reproducibly produce large cell
numbers.
156 EditorialIn this issue of Stem Cell Research two independent
groups produced cardiomyocytes from human embryonic
stem cells and use electrophysiology to asses their response
to a selection of well characterized drugs (Jonsson et al.,
2010; Otsuji et al., 2010). This complements a third paper
published in the previous edition of Stem Cell Research which
showed systematic analyses of cardiac field potentials in
response to a variety of cardiac and non-cardiac drugs
(Braam et al., 2010). All three papers are presented as
potential model systems for evaluating safety pharmacology
of the heart.
The key question that arises from these papers is whether
the models have actually been validated. Do the models
accurately predict the safety liability of a drug candidate
once applied to humans? All three papers provide evidence
that the stem cell derived cardiomyocytes do respond to the
drugs as predicted. For example E-4031, a classical hERG-
blocker was tested in all three papers and demonstrated to
induce a dose dependent prolongation of the field or action
potential. In addition to examining action potential prolon-
gation, the paper of Jonsson et al describes measurement of
parameters like reverse use dependence, triangulation of
the action potential and beat-to-beat variability. It has been
suggested that these parameters often change before action
potential duration (Shah and Hondeghem, 2005). Therefore
it will be of interest in the future to see how these
parameters behave on stem cell derived cardiomyocytes
when drugs are tested that have a well-documented clinical
history. The paper by Braam et al is the first attempt to
compare drug responses of the cells at concentrations
measured in the plasma of patients quantitatively (Braam
et al., 2010).
Whilst the collection of papers represents a good start to
developing this type of drug safety platform, there is clearly
a need for refinement of the differentiation and culture
protocols. For example, whilst Otsuji and colleagues show
that prolonged culture improves the maturation of the cells,
which directly affects the drug response, direct comparison
with concentrations of drugs in patients is not shown and
culture of the cells for up to 8 months in a labor-intensive
protocol is required. This limits the applicability of the
procedure. Jonsson and colleagues show clear heterogeneity
between individual beating clusters with ventricular-like,
atrial-like and nodal-like action potentials. For this reason,
they selected clusters with a ventricular-like action poten-
tial (it is expected that drug effects on cardiomyocytes of the
ventricle are likely to represent the highest drug risk), but
manual selection is not well suited for high throughput
automated analyses. Further development of reproducible
differentiation protocol to a specific cell type (for example
ventricular cardiomyocytes) followed by a maturation step in
a system that can be scaled up will be necessary for the
successful implementation of the stem cell model.
Taken together, whilst the data presented in the three
papers are promising, the technology is still under devel-opment and the models remain to be fully validated. In an
ideal world, drugs would be ranked against a range of other
drugs to generate a ‘clinical ranking order’, which could
assist in validation. For TdP, ranking in this way does not
exist, in part because its incidence is rare and calculations
of its incidence cannot be made with sufficient accuracy.
What needs to be done is validation of the model by testing
a larger panel of compounds in a blinded screening assay. A
range of positive and negative controls would need to be
included with a known effect (or lack of it) in humans. Once
validated in this way, these models may eventually be used
to flag potentially unsafe drugs early in the preclinical
development phase. The sooner a potentially adverse effect
is detected the sooner a company can develop an adequate
risk management strategy. That can involve further
optimization of the lead compound with the aim of
enhancing the risk benefit profile, development of a
whole new drug or, in the worst case, abandoning the
compound. In the long run this could however not only
increase safety but also reduce costs of production since
many later and more expensive assays in whole animals,
like dogs, would not need to be carried out for drugs with
significant safety issues. The studies published here show
that human embryonic stem cell derived cardiomyocytes
have the potential to be developed into a reasonably
inexpensive, predictive human cardiac safety pharmacology
model. This may allow researchers to perform drug
discovery research and cardiac safety pharmacology in
parallel. The outcomes of each process can inform the
decision making in the other, ultimately leading to more
effective drug development.References
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